基于EUSTAR数据库的事后比较:托珠单抗、利妥昔单抗、霉酚酸酯与环磷酰胺在系统性硬化症相关间质性肺病患者中的有效性
本研究基于EUSTAR数据库纳入955例影像学确诊的系统性硬化症相关间质性肺病患者共997次治疗观察,事后比较托珠单抗、利妥昔单抗、霉酚酸酯与环磷酰胺对用力肺活量百分比预测值变化的影响,中位随访11个月。经倾向评分逆概率治疗加权调整后,四组间用力肺活量百分比预测值变化无显著差异(P=0.101),配对比较亦无显著差异。
要点
- 四组间用力肺活量百分比预测值变化的多组比较无显著差异(P=0.101)。
- 配对比较显示托珠单抗、利妥昔单抗、霉酚酸酯与环磷酰胺两两间无显著差异。
- 亚组分析中四组疗效差异在联合免疫抑制、既往暴露及吸烟状态等条件下均不显著。
核心结论
- 在这项首个大型真实世界研究中,托珠单抗、利妥昔单抗、霉酚酸酯与环磷酰胺对系统性硬化症相关间质性肺病患者用力肺活量变化的效果无统计学差异。
研究设计与样本
- 事后研究,纳入EUSTAR数据库中影像学确诊的系统性硬化症相关间质性肺病且具有托珠单抗、利妥昔单抗、霉酚酸酯或环磷酰胺治疗记录的患者。
- 共纳入955例患者、997次治疗观察,中位随访11个月(IQR 8-14个月)。
- 主要终点为基线至随访时用力肺活量百分比预测值的变化,采用基于倾向评分的逆概率治疗加权调整临床和人口学特征、联合治疗及随访时间。
主要发现
- 经逆概率治疗加权后,四组间用力肺活量百分比预测值变化的多组比较无显著差异(P=0.101)。
- 配对比较显示无显著差异。
- 逻辑回归显示环磷酰胺与用力肺活量稳定相关。
- 亚组分析中,在联合免疫抑制治疗、既往暴露于托珠单抗、利妥昔单抗或传统免疫抑制剂、当前吸烟者或非吸烟者、以及观察始于治疗起始或非起始阶段的患者中,四组间用力肺活量百分比预测值变化差异均不显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) most frequently used for systemic sclerosis-associated interstitial lung disease (SSc-ILD). This post hoc study aimed to compare their effectiveness in patients with SSc-ILD from the European Scleroderma Trials and Research (EUSTAR) database. METHODS: We included radiologically confirmed SSc-ILD patients with treatment records for TCZ, RTX, MMF, or CYC. The primary endpoint was the change in forced vital capacity (FVC) percent predicted from baseline to follow-up. Analyses were adjusted for clinical and demographic characteristics, cotreatments, and follow-up duration using propensity score-based inverse probability of treatment weighting (IPTW). RESULTS: Nine hundred fifty-five patients with 997 treatment observations were included in the study. The median follow-up time was 11 months (IQR, 8-14 months). After IPTW, the changes in FVC percent predicted were not significantly different in the multigroup comparison (P = .101). Paired comparisons showed no significant difference. CYC was associated with stable FVC in logistic regression. For subgroup analysis, the treatment differences in change of FVC percent predicted among the 4 groups were not significant in patients with combination IS or previous exposure to TCZ, RTX, or conventional IS, as well as in current smokers or nonsmokers, and regardless of whether observations started either at the initiating or noninitiating stage of the treatment. CONCLUSIONS: In this first large real-world study, the effectiveness of TCZ, RTX, MMF, and CYC on FVC change in SSc-ILD patients was not statistically different.
引用
- Yan Q, Bruni C, Garaiman A, et al. Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database. Ann Rheum Dis. 2025. PMID: 39894689. doi:10.1016/j.ard.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。